Bone marrow free immune checkpoints as a potential biomarker for differential diagnosis of acquired bone marrow failures.

Mengtong Zang Nianbin Li Qiulin Chen NingYuan Ran Wenhui Lei Zonghong Shao Ting Wang

Published in: Journal of clinical laboratory analysis (2022)

In conclusion, we found that there were notable differences in the immune status of AA, ICUS, and MDS. The concentrations of sCD40, sCD86/B7-2, sCTLA-4, sGITR, sHVEM, sPD-1, sTIM-3, and sTLR-2 could be used to identify AA and hypoproliferative MDS patients, as well as to distinguish ICUS patients who could benefit from IST.

Keyphrases

bone marrow
mesenchymal stem cells
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
peritoneal dialysis